Independent report highlights Bioxytran's carbohydrate-based therapeutic platforms, clinical pipeline, and long-term development strategy
BOSTON, Nov. 13, 2025 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics for viral diseases, oxygen transport, and other serious medical conditions, today announced that Independent Research, a global equity research firm focused on micro-cap and emerging growth companies, has initiated independent research coverage of the Company.
The report reviews Bioxytran's scientific platforms, lead clinical programs, and long-term growth strategy, highlighting the Company's differentiated approach to developing investigational therapies based on carbohydrate chemistry, galectin biology, and oxygen transport technologies.
The full Independent Research report is available through the firm's website.
The report reviews the development of ProLectin-M, Bioxytran's lead investigational oral galectin antagonist designed to interfere with viral entry by targeting galectin-mediated biological pathways.
Independent Research discusses clinical findings from the Company's randomized clinical studies, including rapid viral clearance observed in patients with mild-to-moderate COVID-19 and a favorable safety profile. The report also notes the potential applicability of the Company's galectin-targeted approach across multiple viral infections, including influenza and respiratory syncytial virus (RSV), while acknowledging that additional clinical studies will be required to evaluate these indications.
Unlike therapies designed to inhibit viral replication after infection has occurred, ProLectin-M is being investigated as a viral entry inhibitor that targets host-pathogen interactions through galectin modulation. Bioxytran believes this differentiated mechanism represents a promising area of ongoing antiviral research.
Independent Research also highlights BXT-25, Bioxytran's investigational oxygen therapeutic platform being developed to improve oxygen delivery during conditions associated with acute tissue hypoxia.
The report discusses the significant unmet need in acute ischemic stroke, where timely restoration of oxygen delivery remains critical to preserving brain tissue. Bioxytran's oxygen transport technology is being investigated as a potential approach to supporting oxygen delivery during emergency care settings. BXT-25 remains investigational and has not been approved for clinical use.
Beyond stroke, the Company's oxygen therapeutics platform may have future applications across additional diseases characterized by tissue hypoxia and impaired oxygen delivery.
The independent report also notes Bioxytran's significant insider ownership, reflecting management's long-term commitment to advancing the Company's scientific platforms and creating shareholder value.
Bioxytran continues to prioritize disciplined capital allocation while pursuing strategic partnerships, licensing opportunities, and collaborative research initiatives that may support future clinical development.
Independent Research recognizes Bioxytran's broader platform strategy, which extends beyond individual therapeutic candidates.
The Company continues to build proprietary technologies across several scientific areas, including:
By developing platform technologies capable of addressing multiple disease pathways, Bioxytran is creating opportunities for future pipeline expansion, strategic collaborations, and long-term scientific innovation.
Bioxytran's research strategy is centered on understanding disease mechanisms that span multiple therapeutic areas rather than focusing on individual disease targets.
The Company's investigational platforms are designed to explore novel approaches for:
This platform-based approach allows Bioxytran to investigate multiple clinical applications while expanding its proprietary intellectual property portfolio.
Bioxytran, Inc. is a clinical-stage biotechnology company developing investigational carbohydrate-based therapeutics designed to address significant unmet medical needs in viral diseases, hypoxia, inflammation, fibrosis, and related disorders.
The Company's proprietary platform combines glycovirology, galectin biology, carbohydrate chemistry, and oxygen-based therapeutic technologies to investigate new approaches to treating diseases for which conventional therapies remain limited. Its lead investigational programs include ProLectin-M, a galectin antagonist being studied for viral diseases, and BXT-25, an investigational oxygen therapeutic platform designed to improve oxygen delivery during tissue hypoxia.
This news release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding Bioxytran's investigational product candidates, scientific platforms, clinical development programs, strategic partnerships, future regulatory activities, and potential therapeutic applications. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include clinical trial outcomes, regulatory decisions, funding availability, commercialization efforts, strategic collaborations, and other risks described in the Company's filings with the U.S. Securities and Exchange Commission. Bioxytran undertakes no obligation to update forward-looking statements except as required by law.
For more information, please visit:
Visit the original announcement:
https://www.otcmarkets.com/stock/BIXT/news/Bioxytran-Announces-Initiation-of-Coverage-of-its-Stock-by-Independent-Research?id=500012
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
